NSE: AJANTPHARM | BSE: 532331

Mid-range Performer

Download real time

2925.30 62.10 (2.17%)

25.70% Gain from 52W Low

11,274 NSE+BSE Volume

NSE 25 Mar, 2026 10:22 AM (IST)

36,540.5

Market Cap

High in industry

Beta 1Year

Very Low volatility

Ajanta Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AJANTPHARM, BSE:532331 Ajanta Pharma Ltd.

Search Inside the pdf :

Ajanta Pharma Ltd.

01 Feb 2026

2925.30

2.17%

Ajanta Pharma Ltd.

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Branded generics traction, US momentum key differentiators- Branded business growth in India was significantly above the trendline and without one-offs, driven by 16 new launches over the last 9-12 months and improved coverage. The US also maintained the growth tempo on account of 8 new launches over the last 9-12 months and market share gain in the existing products. US traction is contrary to the existing industry trend as the focus remains on specific launches. Africa branded continued to be driven by new launches. Asia branded on the other hand witnessed...

Number of FII/FPI investors decreased from 343 to 316 in Dec 2025 qtr

Ajanta Pharma Ltd.

31 Jan 2026

2925.30

2.17%

Ajanta Pharma (BUY): Healthy earnings momentum to continue

Buy: Ajanta Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT were 7%/12% and 5.6% above our estimates driven by beat across regions. EBITDA margin 130 bps above our estimates

Ajanta Pharma Ltd. has an average target of 3120.83 from 6 brokers.

Ajanta Pharma Ltd.

30 Jan 2026

2925.30

2.17%

Execution drives earnings beat

buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) posted a better-than-expected financial performance in 3QFY26, with 5%/7%/5% beat on revenue/EBITDA/PAT. AJP saw superior execution in Africa, US and domestic formulation (DF), which was offset to some extent by subdued performance in Asia.

Ajanta Pharma Ltd. is trading above its 200 day SMA of 2666.4

Ajanta Pharma Ltd.

29 Dec 2025

2925.30

2.17%

Branded generics playbook fires; semaglutide adds a new growth leg

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

AJP is implementing multiple strategic initiatives across focus branded generics markets of India, Asia, and Africa to sustain robust industry outperformance.

Ajanta Pharma Ltd.'s price crossed above 50Day SMA today

Ajanta Pharma Ltd.

04 Nov 2025

2925.30

2.17%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Q2FY26- Momentum driven by US and India Business - Revenues grew ~14% YoY to 1354 crore driven by US and India branded business which grew ~48% / ~12% to 344 crore and 432 crore, respectively. Other branded businesses such as Asia and Africa witnessed the growth of 5% / 4% (on higher base) to 310 crore and 221 crore, respectively. On the operational front, EBITDA grew 5.4% YoY to ~328 crore (excluding forex losses of 41 crore, 9 % growth to ~369 crore) with margins at 24.2%...

Number of FII/FPI investors decreased from 343 to 316 in Dec 2025 qtr

Ajanta Pharma Ltd.

03 Nov 2025

2925.30

2.17%

Ajanta Pharma (HOLD): US generic sales growth weighs on margins

Hold: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT were 1%/-8%/7% above our estimates. EBITDA margin reported 230 bps below estimates at 24.2%, Adj forex at 27%

Promoters pledged 2.01% of shares in last quarter. Total pledge stands at 17.29% of promoter holdings

Ajanta Pharma Ltd.

03 Nov 2025

2925.30

2.17%

In-line 2Q; growth led by DF/US generics

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP)’s 2QFY26 revenue was slightly above our expectation (3.5% beat). EBITDA and PAT were largely in line and grew at a lower rate compared to revenue growth for the quarter.